Dihydrogenated Alkaloids of Ergotoxine in Non-Hospitalised Elderly Patients

Abstract
A controlled trial of dihydrogenated alkaloids of ergotoxine in 32 elderly patients with arteriosclerotic and in 46 with non-arteriosclerotic dementias was conducted whilst the patients were still in the community. There was a significant improvement in the patients receiving this drug as judged by the improvement of the clinical picture and the length of time before hospitalisation became necessary. The initial improvement was, however, not sustained for the whole duration of the trial.